Valuation: Aquestive Therapeutics, Inc.

Market Cap 473M 430M 398M 358M 676M 44.17B 701M 4.78B 1.89B 23.83B 1.77B 1.74B 75.37B P/E 2026 *
-7.57x
P/E 2027 * -7.94x
Enterprise Value 392M 356M 330M 297M 560M 36.6B 581M 3.96B 1.57B 19.75B 1.47B 1.44B 62.45B EV / Sales 2026 *
7.91x
EV / Sales 2027 * 6.79x
Free-Float
88.81%
Yield 2026 *
-
Yield 2027 * -
1 day-1.60%
1 week+4.52%
Current month-4.88%
1 month-2.12%
3 months-12.94%
6 months-11.27%
Current year-42.72%
1 week 3.45
Extreme 3.45
3.96
1 month 3.37
Extreme 3.37
4.29
Current year 2.93
Extreme 2.93
6.59
1 year 2.93
Extreme 2.93
6.74
3 years 1.73
Extreme 1.73
7.55
5 years 0.62
Extreme 0.618
7.55
10 years 0.62
Extreme 0.618
20.7
Manager TitleAgeSince
Chief Executive Officer 50 17/05/2022
Director of Finance/CFO 67 31/12/2020
Compliance Officer - 02/04/2026
Director TitleAgeSince
Chairman 72 01/04/2024
Director/Board Member 60 01/01/2004
Director/Board Member 50 17/05/2022
Date Insider Type Main position Quantity % Market Cap. Importance
21/10/26 Others

Director

62,229 0.0496%
15/10/26 Sell

Chief Executive Officer

-25,000 0.0199%
15/10/26 Other

Director

0 0.0000% -
Change 5-day change 1-year change 3-year change Capi.($)
-1.60%+4.52%-31.35%+115.12% 473M
-1.13%+0.25%+38.06%+140.43% 1,275B
-1.36%-1.21%+42.24%+85.68% 680B
-0.59%-0.16%+26.02%+111.76% 521B
-0.76%+1.27%+41.98%+71.50% 389B
-0.75%-3.62%+54.29%+40.57% 356B
-1.83%-0.13%+27.64%+60.13% 305B
-1.65%-1.88%+2.00%+35.77% 287B
-0.95%-1.57%+35.99%+70.23% 250B
+1.60%+0.56%+36.19%+128.48% 208B
Average -0.71%+1.08%+27.31%+85.97% 427B
Weighted average by Cap. -0.75%+0.76%+35.58%+96.15%

Financials

2026 *2027 *
Net sales 49.5M 45.03M 41.66M 37.49M 70.78M 4.63B 73.46M 500M 198M 2.5B 186M 182M 7.89B 69.64M 63.35M 58.61M 52.75M 99.58M 6.51B 103M 704M 278M 3.51B 261M 256M 11.11B
Net income -61.28M -55.74M -51.57M -46.41M -87.62M -5.73B -90.94M -619M -245M -3.09B -230M -225M -9.77B -59.14M -53.79M -49.77M -44.79M -84.56M -5.53B -87.76M -598M -236M -2.98B -222M -217M -9.43B
Net Debt -81M -73.68M -68.17M -61.35M -116M -7.57B -120M -819M -324M -4.08B -304M -297M -12.92B -
Projected Income Statement - Annual - Aquestive Therapeutics, Inc.
Logo Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.
Employees
147
Date Price Change Volume
17/11/26 US$3.700 -1.60% 2,116,267
16/11/26 US$3.760 -3.84% 2,000,321
13/11/26 US$3.910 +9.52% 3,966,973
12/11/26 US$3.570 -0.28% 2,795,617
11/11/26 US$3.580 +1.70% 2,179,689
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Aquestive Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
3.760USD
Average target price
9.333USD
Spread / Average Target
+148.23%
  1. Stock Market
  2. Stocks
  3. AQST Stock